{"product_id":"entx-pestle-analysis","title":"(ENTX) Entera Bio Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Entera Bio Ltd. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investment. This page shows a real preview of the report so you can judge style and depth; purchase the full version to get the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio is headquartered in Jerusalem, so Israeli domestic policy, tax rules, and life-science grants can affect hiring, funding, and clinical execution. Israel spends about 6.0% of GDP on R\u0026amp;D, one of the highest rates globally, which supports biotech talent and trial support. Regional security shifts can still disrupt site access, shipments, and patient visits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.'s programs are in Phase I and Phase II, so health regulators and ethics boards can shape every trial step, from site start-up to protocol edits. In the U.S., FDA IND reviews and IRB approvals can add weeks or months, and a single amendment can reset timelines. Political support for biotech R\u0026amp;D matters because faster reviews can speed data readouts and capital use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-border partnership with Amgen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s pact with Amgen Inc., a U.S. biotech with sales in 100+ countries, makes this political risk global. Cross-border value depends on trade policy, IP rules, and fast regulatory alignment between the U.S. and Israel, plus any changes in U.S. science funding or drug pricing rules. Strong diplomatic ties can lower friction, but any export, tax, or data-sharing shift can slow partner value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare priority area\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHypoparathyroidism, osteoporosis, and fracture repair are high-need areas: osteoporosis affects about 200 million people worldwide, and fragility fractures exceed 8.9 million a year. Public health systems often favor therapies that address severe unmet need and long-term disability.\u003c\/p\u003e\n\u003cp\u003eFor Entera Bio Ltd, this policy bias can support adoption if its medicines show clear clinical value and lower downstream costs, especially in chronic care settings where fracture risk drives hospital use and rehab spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200 million people live with osteoporosis worldwide.\u003c\/li\u003e\n\u003cli\u003e8.9 million fragility fractures occur each year.\u003c\/li\u003e\n\u003cli\u003eAccess-focused policy can speed uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic funding environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntera Bio Ltd. benefits from Israel’s strong public R\u0026amp;D base: national gross R\u0026amp;D spending was about 6.3% of GDP in 2023, one of the highest in the OECD. That kind of state support helps biopharma firms access grants, incubators, and early research funding before revenues arrive. Still, if public budgets tighten, non-dilutive capital can shrink fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eIsrael supports early-stage biotech.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePublic funding can cut dilution risk.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBudget swings can slow R\u0026amp;D financing.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael Policy, FDA Timing, and Security Risks Shape Entera Bio’s Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. faces political risk from Israeli policy, tax, and grant changes, since Israel still backs biotech with high R\u0026amp;D spend. Its cross-border work with Amgen Inc. also depends on U.S.-Israel trade, IP, and data rules. FDA and IRB timing can shift trial starts and amendment cycles. Regional security can disrupt sites and shipments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6.3% of GDP, 2023\u003c\/td\u003e\n\u003ctd\u003eSupports grants and talent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOsteoporosis need\u003c\/td\u003e\n\u003ctd\u003e200M people\u003c\/td\u003e\n\u003ctd\u003eCan favor access policies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragility fractures\u003c\/td\u003e\n\u003ctd\u003e8.9M a year\u003c\/td\u003e\n\u003ctd\u003eRaises public-health demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the key Political, Economic, Social, Technological, Environmental, and Legal forces shaping Entera Bio Ltd.’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Entera Bio Ltd. PESTLE summary that simplifies external risk review and speeds strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary sources and industry data that speeds investor due diligence on Entera Bio Ltd.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 lead drug programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio’s pipeline is still centered on two lead programs, EB612 and EB613, so R\u0026amp;D spend and management focus stay concentrated. That lowers operating complexity, but it also makes the Company more exposed to any setback in just one asset. In 2025, each milestone on EB612 or EB613 carried outsized economic value because there are only 2 shots on goal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage business model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd has no marketed product, so commercial drug sales were 0 in 2025 and the business still depended on R\u0026amp;D spending, not product cash flow.\u003c\/p\u003e\n\u003cp\u003eFor clinical-stage biopharma, external funding is the key economic driver: equity raises, grants, and partner cash help cover trial costs long before approval.\u003c\/p\u003e\n\u003cp\u003eThat makes cash runway and access to capital critical; if financing tightens, trial pace slows and dilution risk rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II to Phase I transition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. is shifting EB613 from Phase II osteoporosis work into Phase I for non-healing fractures while EB612 stays in Phase II, so R\u0026amp;D burn stays high across both programs. Trial steps like this usually lift valuation expectations, but they also add spending on studies, GMP manufacturing, and FDA\/EMA work; Entera Bio Ltd. reported a 2024 cash balance of about $22.6 million, underscoring how much funding the pipeline still needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-driven economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntera Bio Ltd.'s Amgen collaboration can bring non-dilutive cash through research funding and licensing economics, which helps cut the company’s standalone R\u0026amp;D burden. Deals like this also act as external validation of Entera Bio Ltd.’s platform, which can support partner interest and lower future funding pressure.\u003c\/p\u003e\n\u003cp\u003eAny milestone or royalty stream would add upside without immediate equity dilution, improving Entera Bio Ltd.’s funding flexibility if programs advance. That matters most when cash needs rise before product revenue starts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-dilutive support reduces dilution risk\u003c\/li\u003e\n\u003cli\u003ePartner validation can ease future fundraising\u003c\/li\u003e\n\u003cli\u003eMilestones and royalties add flexible upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-cap biotech funding pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall-cap biotech funding stays tight for Entera Bio Ltd because loss-making drug developers still trade on trial news, not steady cash flow. Higher rates keep capital expensive: the U.S. federal funds target stayed at 5.25% to 5.50% through much of 2025, so equity raises can be more dilutive and debt harder to secure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial data can move sentiment fast.\u003c\/li\u003e\n\u003cli\u003eHigh rates lift funding costs.\u003c\/li\u003e\n\u003cli\u003eSmall caps face tougher dilution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntera Bio’s Cash Burn Keeps Dilution Risk in Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. remains economically dependent on external capital because it had no product revenue in 2025 and kept funding EB612 and EB613 through R\u0026amp;D spend. The Company’s 2024 cash balance was about $22.6 million, so runway and dilution risk stay central. Higher rates in 2025 also kept biotech funding costly, which can slow trial pace if markets tighten.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey economic item\u003c\/th\u003e\n\u003cth\u003e2025\/2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash balance\u003c\/td\u003e\n\u003ctd\u003eAbout $22.6 million in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead programs\u003c\/td\u003e\n\u003ctd\u003eEB612 and EB613\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRate backdrop\u003c\/td\u003e\n\u003ctd\u003e5.25% to 5.50% federal funds target in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEntera Bio Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Entera Bio Ltd. PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmet-need indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEB612 targets hypoparathyroidism, a rare disorder with about 70,000 people affected in the U.S., while EB613 targets osteoporosis and non-healing fractures, where fracture nonunion affects roughly 5% to 10% of broken bones. These conditions can cut mobility, independence, and day-to-day quality of life. Patient demand stays high because current treatments often fail to restore normal bone and calcium balance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAge-related bone disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeople aged 65+ are set to hit 1.6 billion by 2050, up from 771 million in 2022, and osteoporosis causes about 8.9 million fractures each year worldwide. As people live longer, bone-loss and slow fracture repair become bigger social issues, with mobility and independence at stake. That gives Entera Bio Ltd. a clear role in therapies that help healing and cut complications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral treatment preference\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s oral large-molecule focus fits a strong social shift toward easier dosing, since pills are usually simpler than injections or infusions. In chronic care, better convenience can lift adherence, and adherence matters because even small drops can worsen outcomes and raise care costs. This preference supports demand for oral options as patients and caregivers look for less disruptive treatment routines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic disease burden supports Entera Bio Ltd. because its targets are long-term, recurring conditions that need steady therapy. WHO says chronic diseases cause about 74% of global deaths, so demand for effective, tolerable treatments stays high. Patients also want daily-life fit, which favors oral, convenient options over complex regimens.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e74% of global deaths are chronic.\u003c\/li\u003e\n\u003cli\u003eLong-term illness drives repeat treatment need.\u003c\/li\u003e\n\u003cli\u003eConvenience shapes patient choice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialist-driven adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntera Bio Ltd.'s uptake depends on endocrinologists and orthopedists, because osteoporosis and related bone-loss care is specialist-led. Physician trust, guideline support, and real-world fracture data will drive adoption, especially with osteoporosis affecting about 10 million Americans and causing more than 2 million fractures each year. Education and evidence are central to switching care patterns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialists control prescribing.\u003c\/li\u003e\n\u003cli\u003eGuidelines shape uptake.\u003c\/li\u003e\n\u003cli\u003eReal-world outcomes matter most.\u003c\/li\u003e\n\u003cli\u003eEvidence must beat inertia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging and fractures fuel demand for simpler oral bone care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. benefits from aging societies: people 65+ should reach 1.6 billion by 2050, and osteoporosis already drives about 8.9 million fractures a year worldwide. Patients with hypoparathyroidism and fracture nonunion want simpler, oral care that fits daily life, so convenience can lift adherence. Specialist-led prescribing and guideline support will still decide uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e1.6B aged 65+ by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFractures\u003c\/td\u003e\n\u003ctd\u003e8.9M yearly worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003eOral dosing improves fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral large-molecule platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio’s oral large-molecule platform targets a hard problem: peptides and proteins usually break down in the GI tract, and many oral candidates have bioavailability below 1%. That makes platform performance the key moat, because even small gains in absorption can change dose, safety, and efficacy. In 2025, this is still one of the toughest drug-delivery tasks in biotech, with oral biologics remaining a small share of the pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEB612 Phase II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEB612 is in Phase II clinical testing for hypoparathyroidism, where companies usually look for early efficacy signals and dose response before a larger trial. Phase II results can support later-stage development if they show meaningful control of calcium levels and safety. For Entera Bio Ltd., this stage matters because Phase II data often drive the next funding and trial-design decision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEB613 Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEB613 has finished Phase II in osteoporosis and is now in Phase I for non-healing bone fractures, so Entera Bio Ltd. is adding fresh safety and proof-of-concept data before it can widen use. That multi-indication push matters because fracture healing has a different risk profile than osteoporosis, and early-stage studies usually track safety plus dose response in small patient groups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiologics formulation complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiologics oral delivery is still a hard science: proteins and peptides are fragile, and oral bioavailability for semaglutide is only about 0.4% to 1%, so tiny gains can change program economics fast. Entera Bio Ltd. needs tight control of stability, absorption enhancers, and batch-to-batch consistency. Scale-up is just as important, because a formula that works in the lab can fail in manufacturing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.4%-1% oral semaglutide bioavailability\u003c\/li\u003e\n\u003cli\u003eStability drives oral biologic success\u003c\/li\u003e\n\u003cli\u003eScale-up risk can kill value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch collaboration with Amgen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Amgen pact gives Entera Bio Ltd. access to a much larger R\u0026amp;D engine, helping identify and develop candidate compounds for inflammatory and other serious diseases. Shared work broadens scientific scope and can speed target validation and technical learning. This matters because Amgen is a top-tier biotech R\u0026amp;D spender, so the collaboration can raise Entera Bio Ltd.'s hit rate without building all expertise in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to external scientific expertise\u003c\/li\u003e\n\u003cli\u003eBroader disease and target coverage\u003c\/li\u003e\n\u003cli\u003eFaster validation, lower development risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntera Bio's Oral Delivery Test: Can the Platform Prove It?\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnological risk for Entera Bio Ltd. is still centered on oral delivery of fragile peptides and proteins, where even small absorption gains can change the whole program. EB612 is in Phase II and EB613 has moved to Phase I, so the key test is whether the platform can keep showing stable bioavailability, safety, and scalable manufacturing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral semaglutide bioavailability\u003c\/td\u003e\n\u003ctd\u003e0.4% to 1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB612 stage\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB613 stage\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s Phase I and Phase II studies must follow protocol, ethics approval, informed consent, and safety reporting rules; these trials often enroll only 20-100 patients, so one lapse can trigger a hold. Regulators can pause development fast if human-subject protections or adverse-event reporting fail. For a small biotech like Entera Bio Ltd., that legal risk can directly delay data readouts and raise trial costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug approval pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. cannot commercialize a product until regulators clear safety, efficacy, and manufacturing quality data. For an oral peptide or protein candidate, that usually means staged FDA and other agency reviews, with any CMC gap delaying filing or approval. This legally constrains timelines because Entera Bio must finish preclinical work, clinical trials, and process validation before launch. In practice, the drug approval pathway is a gate, not a formality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing agreement terms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s Amgen deal has both research and licensing terms, so the contract scope matters for who controls development, data, and follow-on rights. Milestone triggers, exclusivity, and IP ownership can change future cash flows and limit strategic freedom. In 2025 filings, these terms remained legally material because they can decide who keeps rights to resulting assets and who pays if goals are met.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s oral large-molecule pipeline depends on strong patent coverage, because weak IP can cut partner interest and narrow pricing power. Patent scope shapes who can copy the platform and how much leverage Entera Bio Ltd. has in licensing talks. Any IP dispute could delay or block commercialization, which matters in a market where one failed legal claim can erase years of R\u0026amp;D value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong patents protect oral delivery economics.\u003c\/li\u003e\n\u003cli\u003eBroader scope lifts partner value.\u003c\/li\u003e\n\u003cli\u003eIP fights can delay commercialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-jurisdiction operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntera Bio Ltd. faces cross-jurisdiction legal risk because it operates in Israel while working with US partners, so one project can trigger Israeli and US rules at the same time. Data handling, contracts, and regulatory filings may need to meet two legal systems, including privacy, export, and disclosure rules. That lifts compliance cost and can slow submissions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDual legal review is often required.\u003c\/li\u003e\n\u003cli\u003ePrivacy rules can differ by country.\u003c\/li\u003e\n\u003cli\u003eContract terms need two-law checks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntera Bio’s Legal Risks Could Delay Trials and Erase Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s legal risk sits in trial compliance, FDA\/EMA filing rules, and contract control. In 2025 filings, its Amgen deal, patent scope, and cross-border data duties stayed key because they shape who owns rights, who pays milestones, and how fast assets can move. For a small biotech, one IP or ethics issue can delay data, raise costs, and weaken valuation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003e2025 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial compliance\u003c\/td\u003e\n\u003ctd\u003eCan trigger clinical holds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent scope\u003c\/td\u003e\n\u003ctd\u003eProtects oral delivery value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmgen contract\u003c\/td\u003e\n\u003ctd\u003eSets rights and milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCross-border rules\u003c\/td\u003e\n\u003ctd\u003eRaises compliance cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume lab footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio remained clinical-stage in 2025, so its environmental footprint is far smaller than a commercial drug maker's. Most impact comes from lab work, clinical trial materials, and outsourced CMC manufacturing, not in-house plants. Waste handling is still key, especially for biohazard, solvent, and single-use supply waste. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical waste control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd. must manage chemical, biological, and sharps waste from biotech work under strict segregation and vendor controls. WHO says about 15% of healthcare waste is hazardous, so mislabeled bins or weak pickup oversight can quickly raise worker and environmental risk. Good control cuts spill, exposure, and disposal cost pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s R\u0026amp;D labs and cold-chain storage draw steady power, since temperature-sensitive samples need tight control day and night. Energy efficiency steps like better insulation, smart HVAC, and LED lighting can cut use by 20% to 30% in lab settings. That lowers operating costs and can also trim Scope 2 emissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical supply logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMulti-site trials increase Entera Bio Ltd.'s logistics footprint because each site adds more trial-material shipments, packaging, and often temperature-controlled transport. More geography means more road and air freight, so transport emissions rise and waste from single-use packs grows. Tight supply planning, right-sized inventory, and fewer emergency reships can cut both cost and environmental load.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore sites, more shipments\u003c\/li\u003e\n\u003cli\u003ePackaging waste rises fast\u003c\/li\u003e\n\u003cli\u003ePlanning cuts emissions and waste\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate and resilience risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJerusalem-based operations face rising climate stress, including hotter summers, water strain, and power or transport disruption that can slow labs, data systems, and trial work. For Entera Bio Ltd., business continuity planning is not optional: backup power, remote access, and site redundancy protect research timelines and sample integrity. Environmental resilience is now part of operational risk management, especially as extreme-heat and outage events can hit biotech workflows with little warning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtect labs with backup power.\u003c\/li\u003e\n\u003cli\u003eTest data recovery and remote access.\u003c\/li\u003e\n\u003cli\u003eMap alternate trial coordination paths.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntera Bio’s Light Footprint Hides Key Waste and Energy Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntera Bio Ltd.’s environmental impact stayed light in 2025 because it remained clinical-stage, with no commercial plants to manage. Most risk sits in lab waste, cold-chain energy use, and outsourced trial logistics, where single-use packs and temperature control raise both waste and Scope 2 emissions. Climate stress in Jerusalem also makes backup power and remote access key for continuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous healthcare waste\u003c\/td\u003e\n\u003ctd\u003eAbout 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab energy cuts\u003c\/td\u003e\n\u003ctd\u003e20% to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain footprint drivers\u003c\/td\u003e\n\u003ctd\u003eWaste, cold chain, freight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234322161929,"sku":"entx-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/entx-pestle-analysis.webp?v=1785717833","url":"https:\/\/dcfanalyst.com\/products\/entx-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}